Compare USEA & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USEA | MRKR |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 19.5M |
| IPO Year | 2022 | 2010 |
| Metric | USEA | MRKR |
|---|---|---|
| Price | $2.49 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.87 |
| AVG Volume (30 Days) | 79.8K | ★ 169.0K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | ★ 8.98% | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.16 | $19.61 |
| Revenue Next Year | N/A | $375.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.42 | $0.84 |
| 52 Week High | $3.20 | $2.46 |
| Indicator | USEA | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 40.24 |
| Support Level | $2.46 | $0.88 |
| Resistance Level | $2.63 | $1.32 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 35.98 | 9.27 |
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).